Aquestive (AQST) Q3 2026 Earnings Call Transcript

Aquestive Therapeutics reported Q3 2026 revenue of $7.6 million, down 41% from $12.8 million a year earlier, and a net loss of $16.5 million versus $15.4 million; adjusted EBITDA loss widened to $12.2 million from $8.6 million. Management maintained 2026 revenue guidance of $46 million-$50 million and expects year-end cash above $70 million. The FDA accepted the resubmitted Anaphylm NDA with a March 16, 2027 PDUFA date; potential $95 million in RTW and Oaktree funding remains conditional on approval and other requirements. Aquestive also received a $10 million upfront payment for licensing Libervant to Eton, with up to $47.5 million in contingent milestones and mid-teens royalties.

Analysis

AQST is increasingly a binary launch-readiness trade, not a clean near-term revenue-growth story. The key value inflection is whether the March 2027 FDA decision converts into credible payer access and physician adoption—not simply whether the review reaches its stated date. Management’s focus on pharmacodynamic response and ease of carrying is a commercial thesis; it still needs independent clinical interpretation and evidence that prescribers will switch, particularly if payers resist a premium to established alternatives such as Neffy and generic auto-injectors.

The financing headline is conditional, not committed liquidity: failure to meet approval deadlines or other agreement terms could remove access to $95 million just as launch spending rises. If approved, RTW funding may ease equity pressure, while the Oaktree facility adds debt exposure. Separately, order-driven manufacturing revenue makes quarterly cash generation noisy; do not treat one weak quarter as proof of structural demand loss, or a better quarter as a durable recovery. Libervant transfers U.S. commercialization execution to Eton, but AQST’s milestones and royalties depend on approval and actual sales; continued supply also leaves AQST exposed to product-volume variability.

Near term, the PDUFA review and payer updates dominate. Over 1–3 months, monitor FDA requests, inspection activity, and evidence of formulary progress. Over 6–18 months, launch uptake, access quality, and sales-force productivity determine whether the story warrants a commercial multiple. The contrarian risk is that investors overvalue the speed narrative while underweighting coverage friction, patient switching behavior, and the cost of building demand. Conversely, a narrowly resolved CRL with strong coverage could make the market underprice the platform’s follow-on optionality. No valuation or contract terms are provided to support a high-conviction outright position.

Key Decisions for Investors

• Do not chase AQST solely on the resubmission or management’s launch claims. Treat the March 16, 2027 PDUFA as a binary catalyst; reassess after material FDA feedback and independently verifiable payer updates.
• If taking event exposure, prefer a defined-risk AQST call spread sized to tolerate a full loss, entered only when option pricing and liquidity are reviewed. Avoid unhedged common-stock exposure into the decision without a downside budget.
• Track the share price and financing documents alongside FDA timing: a missed review date, approval outside the RTW/Oaktree eligibility window, or adverse funding conditions would falsify the reduced-dilution thesis. Verify facility terms before assigning value to the $95 million.
• For ETON, treat Libervant as contingent upside rather than a near-term earnings catalyst. Monitor regulatory timing, launch readiness, and disclosed sales before positioning; milestone and royalty value cannot be underwritten from the agreement headline alone.
• Key AQST post-approval checks: formulary coverage and restrictions, prescription uptake among targeted specialists, launch spending per uptake, and whether manufacturing revenue stabilizes. Weak access or escalating spend despite approval would invalidate the bull case.